Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Southwest Airlines Co (LUV) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Southwest Airlines Co — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.85 (market cap $4.49B), while Southwest Airlines Co trades at $48.55 (market cap $24.16B). The key difference: Southwest Airlines Co is far larger — about 5.4× ACADIA Pharmaceuticals Inc.'s market cap, and Southwest Airlines Co pays a 1.46% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | LUV | |
|---|---|---|
Market Cap | $4.49B | $24.16B |
Sector | Health | Industrials |
52-Week High | $28.06 | $54.80 |
52-Week Low | $20.06 | $29.06 |
Enterprise Value | $3.69B | $27.23B |
Dividend Yield | — | 1.46% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
Southwest Airlines (LUV) trades at $49.43, down 1.63% today, with a bullish technical signal from moving averages. The company reported revenue of $28.06B in 2025, with a net income margin of 2.83%, and has beaten earnings estimates in two of the last three quarters. Recent news highlights sector optimism due to lower fuel costs and strong travel demand, with analyst consensus leaning toward a buy rating and a $52.47 price target.
The outlook for LUV is cautiously optimistic, supported by earnings growth potential and favorable industry trends, but risks include volatile fuel prices and competitive pressures. The stock presents a moderate opportunity for investors seeking exposure to the airline sector, with upside to the consensus target but sensitivity to macroeconomic conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Southwest Airlines Co
Southwest Airlines is the largest domestic carrier in the United States, as measured by the number of originating passengers boarded. Southwest operates over 700 aircraft in an all-Boeing 737 fleet. Despite expanding into longer routes and business travel, the airline still specializes in short-haul leisure flights, using a point-to-point network. Southwest operates a low-cost carrier business model.
Read more on LUV →
